Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Kushi Kullar who wrote (2404)	12/20/1998 6:10:00 PM
From: Darrel McPherson	Read Replies (2) \| Respond to of 4676

The recent purchase of technology from Gilead has me wondering... "This acquisition is consistent with Isis' strategy to build on its leadership position in antisense technology," said B. Lynne Parshall, Executive Vice President and Chief Financial Officer of Isis. "Isis is committed to consolidating and supplementing our dominant proprietary patent position in antisense with the hope that this technology will fulfill its promise as a revolutionary drug discovery tool." OK, but half expired on the patents? I have asked Isis to elaborate on this "strategy". Is there some part of the deal where GILD still has a position in this? Or does GILD really see this as a nonproductive area? I am more than curious, there is something really big in this deal or really stupid. I vote for big. Anybody else?